|
KMID : 0361520120230030088
|
|
Korean Journal of Psychopharmacology
2012 Volume.23 No. 3 p.88 ~ p.96
|
|
|
An Open Label Multi-Center Prospective Observational Study of Paliperidone Extended Release to Assess the Medication Satisfaction and Treatment Response in Patients with Schizophrenia
|
|
Lee Bong-Ju
Shin Dong-Hwan
Seo Man-Kil
Lee Yo-Han
Yang Dong-Seok
Pac Jin-Woo
Lee Ju-Yeon
Bahk Won-Myong
Jun Tae-Youn
Lee Sang-Kyu
Chae Beang-Jin
Kim Kyung-Sik
Jeong Eun-Jung
Do Seok-Young
Jang Yong-E
Lee Jong-Il
Jeong Jae-Yeol
Kim Sang-Hoon
Yoon Bo-Hyun
Kim Shin-Gyeom
Lee Moon-Soo
Roh Jae-Woo
Gim Min-Sook
Choi Sung-Ku
Kim Young-Hoon
|
|
|
Abstract
|
|
|
Objective: The aim of this study was to demonstrate changes of subjective medication satisfaction and clinical benefit after once-daily paliperidone extended release (ER) in treatment of schizophrenia.
Methods: In an open-label, observational, and multicenter study, 374 patients with schizophrenia who switched to paliperidone ER due to any reason were recruited. Medication Satisfaction Questionnaire (MSQ), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement and visual analogue scale for sleep (VAS) were assessed at baseline, 4 weeks and 8 weeks after treatment. We also examined the type, frequency, and severity of adverse events newly formed.
Results: Among 374 patients, 320 patients (76.5%) were included in the intent-to-treat analysis set. The mean dose of paliperidone ER was 5.33±2.31 mg/day at the initiation. At the endpoint, the mean dose of paliperidone ER was 6.68±3.13 mg/day. The percentages of patients satisfied with medication were changed from 40.9% at baseline to 67.8% at endpoint (p<0.001). Both CGI-S scores and VAS for daytime drowsiness were significantly decreased after 8 weeks (both p<0.0001) and mean scores of MSQ and VAS for sleep quality were improved after 8 weeks (both p<0.0001).
Conclusion: After switching to paliperidone ER, 67.8% of patients with schizophrenia who had any reason to switch medication showed subjective satisfaction for medication and clinical improvement without significant adverse events. Regarding that medication satisfaction was associated with changes of clinical states, medication satisfaction can be used for measures for clinical scales in the treatment of schizophrenia.
|
|
|
KEYWORD
|
|
|
Paliperidone ER, Schizophrenia, Medication satisfaction questionnaire
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|